Arcticar
Arcticar, Inc.
Arctic Therapeutics is a clinical-stage biopharmaceutical company that leverages Iceland's unique genetic data to identify disease causes and develop novel treatments. The company focuses on genetically-targeted therapies for rare and common conditions, primarily in the areas of familial dementia, Alzheimer's disease, and inflammatory skin diseases. Its business model centers on advancing its pipeline of drug candidates through clinical trials and forming strategic partnerships for late-stage development and commercialization.
Products & Team
AT-001
AT-001 is an oral therapeutic designed to prevent and dissolve amyloid plaques and tau tangles, which are key drivers of various dementias. It is being developed as a treatment for a rare, inherited fatal disease called Hereditary Cystatin C Amyloid Angiopathy (HCCAA) and shows potential for treating the broader Alzheimer's disease population. The European Medicines Agency (EMA) has approved a pivotal phase IIb/III clinical trial for this candidate.
AT-001 addresses a significant unmet medical need by offering a potential treatment for fatal neurodegenerative diseases that currently have no cure, such as HCCAA, and could provide a novel therapeutic option for Alzheimer's disease.
Patients are afflicted with severe, often fatal, or chronic debilitating conditions with very limited or no effective treatment options. These pain points include the progressive cognitive decline in dementia, the fatal prognosis of diseases like HCCAA, and the chronic physical discomfort and social impact of severe skin diseases.